Kairos Pharma, LTD. 10-K

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Financial Statements Page Report of Independent Registered Public Accounting Firm – Marcum LLP (PCAOB Firm ID: 688 ) F-1 Consolidated Balance Sheets as of December 31, 2024 and 2023 F-2 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 F-3 Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023 F-4 Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F-5 Notes to Consolidated Financial Statements F-6 116 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Kairos Pharma, Ltd. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet s of Kairos Pharma, Ltd. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, shareholders’ equity (deficit) and cash flows for each of two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023 , and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit s . We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit s in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit s to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit s included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit s also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit s provide a reasonable basis for our opinion. /s/ Marcum LLP Marcum LLP We have served as the Company’s auditor since 2021. Los Angeles, California April 15, 2025 F- 1 Kairos Pharma, Ltd. Consolidated Balance Sheets (In thousands, except for share amounts and par value data) 2024 2023 December 31, 2024 2023 ASSETS Current Assets Cash $ 1,272 $ 93 Vendor advances, net 2,859 - Prepaid expenses and other current assets 38 8 Total Current Assets 4,169 101 Deferred offering costs 1,377 482 Intangible assets, net 222 382 Total Other Assets 1,599 864 TOTAL ASSETS $ 5,768 $ 965 LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued expenses $ 992 $ 2,401 Due to related parties - 4 Total Current Liabilities 992 2,405 Convertible notes payable, net of debt discount of $ 105 at December 31, 2023 - 638 Total Liabilities 992 3,043 Commitments and contingencies - Notes 7 and 11 - - Shareholders’ Equity (Deficit) Preferred stock, par value $ 0.001 , 20,000,000 shares authorized; no shares issued and outstanding, respectively; - - Common stock, par value $ 0.001 , 100,000,000 shares authorized; 13,736,597 and 10,562,640 shares issued and outstanding, respectively; 14 11 Additional paid-in capital 13,577 4,123 Accumulated deficit ( 8,815 ) ( 6,212 ) Total Shareholders’ Equity (Deficit) 4,776 ( 2,078 ) TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) $ 5,768 $ 965 The accompanying notes are an integral part of these consolidated financial statements. F- 2 Kairos Pharma, Ltd. Consolidated Statements of Operations (in thousands, except for share amounts and per share data) 2024 2023 Years Ended December 31, 2024 2023 Revenues $ - $ - Operating expenses: Research and development 414 82 General and administrative 1,929 1,632 Total operating expenses 2,343 1,714 Loss from operations ( 2,343 ) ( 1,714 ) Other income (expenses): Interest expense ( 35 ) ( 42 ) Debt discount amortization ( 154 ) ( 56 ) Financing costs ( 670 ) - Gain on settlement of accounts payable 599 - Total other expenses, net ( 260 ) ( 98 ) NET LOSS $ ( 2,603 ) $ ( 1,812 ) BASIC AND DILUTED LOSS PER COMMON SHARE $ ( 0.23 ) $ ( 0.17 ) WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED 11,356,451 10,382,515 The accompanying notes are an integral part of these consolidated financial statements. F- 3 Kairos Pharma, Ltd. Consolidated Statements of Shareholders’ Equity (Deficit) (in thousands, except share amounts) Shares Amount Capital Deficit Total Additional Common Stock Paid-in Accumulated Shares Amount Capital Deficit Total Balance, December 31, 2022 10,334,357 $ 10 $ 3,211 $ ( 4,400 ) $ ( 1,179 ) Fair value of shares issued in connection with shareholder dispute 228,223 912 - 912 Net loss - - - ( 1,812 ) ( 1,812 ) Balance, December 31, 2023 10,562,640 $ 11 $ 4,123 $ ( 6,212 ) $ ( 2,078 ) Balance 10,562,640 $ 11 $ 4,123 $ ( 6,212 ) $ ( 2,078 ) Issuance of common shares upon the closing of the initial public offering, net of offering costs 1,550,000 2 4,650 - 4,652 Issuance of common shares upon conversion of convertible notes payable and accrued interest 368,371 - 884 - 884 Issuance of common shares upon conversion of accounts payable 514,940 - 1,789 - 1,789 Issuance of common shares upon conversion of amounts due to related parties 1,664 - 7 - 7 Issuance of common shares for deferred offering costs 670,641 1 1,877 1,878 Warrants issued in connection with convertible notes payable - - 29 - 29 Stock-based compensation 68,341 - 218 - 218 Net loss - - - ( 2,603 ) ( 2,603 ) Balance, December 31, 2024 13,736,597 $ 14 $ 13,577 $ ( 8,815 ) $ 4,776 Balance 13,736,597 $ 14 $ 13,577 $ ( 8,815 ) $ 4,776 The accompanying notes are an integral part of these consolidated financial statements. F- 4 Kairos Pharma, Ltd. Consolidated Statements of Cash Flows (In thousands) 2024 2023 Years Ended December 31, 2024 2023 Cash Flows from Operating Activities Net loss $ ( 2,603 ) $ ( 1,812 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Amortization expense - intangible asset 160 160 Amortization of debt discount 154 56 Common stock issued in connection with shareholder dispute - 913 Financing costs in connection with the conversion of accounts payable 670 - Stock-based compensation 218 - Warrants issued in connection with convertible notes payable 29 - Gain on settlement of accounts payable ( 599 ) Changes in operating assets and liabilities: Vendor advances ( 2,358 ) - Prepaid expenses and other current assets ( 30 ) ( 8 ) Accounts payable and accrued expenses 404 772 Net cash provided by (used in) operating activities ( 3,955 ) 81 Cash Flows from Financing Activities Proceeds from common stock issued for cash in connection with the closing of the initial public offering 5,524 - Proceeds from notes payable - officers 142 - Repayment of notes payable - officers ( 142 ) - Payment of deferred offering costs ( 390 ) ( 425 ) Net cash provided by (used in) financing activities 5,134 ( 425 ) Net increase (decrease) in cash 1,179 ( 344 ) Cash beginning of year 93 437 Cash end of year $ 1,272 $ 93 Supplemental cash flows disclosures: Interest paid $ 3 $ - Taxes paid $ - $ - Supplemental non-cash financing disclosures: Issuance of common shares for deferred offering costs $ 1,377 $ - Issuance of common shares for vendor advances $ 500 $ - Reclassification of deferred offering costs to shareholders’ equity $ 872 $ - Conversion of convertible notes payable and accrued interest to shareholders’ equity $ 884 $ - Conversion of accounts payable to shareholders’ equity $ 1,348 $ - Conversion of amounts due to related parties to shareholders’ equity $ 4 $ - Issuance of convertible notes payable recorded as debt discount $ 49 $ 68 The accompanying notes are an integral part of these consolidated financial statements. F- 5 KAIROS PHARMA, LTD. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In thousands, except for share amounts and per share data) NOTE 1 – BASIS OF PRESENTATION Organization and Operations Kairos Pharma, Ltd. (the “Company” or “Kairos”) was incorporated on June 17, 2013 under the laws of the state of California as NanoGB13, Inc. The Company changed its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation under the same name, Kairos Pharm, Ltd., on May 10, 2023. The Company is an early-stage biotechnology company focused on the development of immunotherapy and cell therapy treatments for oncology. Liquidity and Capital Resources The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the year ended December 31, 2023, the Company incurred a net loss of $ 1,812 and had a shareholders’ deficit of $ 2,078 as of December 31, 2023. During the year ended December 31, 2024, the Company incurred a net loss of $ 2,603 and used cash in operations of $ 3,955 . During the year ended December 31, 2024, the Company completed its initial public offering (“IPO”) and received $ 5,524 of net proceeds, before deducting deferred offering costs. Due to the funds received through the IPO, as well as the conversion of convertible notes payable and certain accounts payable upon closing of the IPO, at December 31, 2024, the Company had cash totaling $ 1,272 and shareholders’ equity of $ 4,776 . In January 2025, the Company closed a private financing in which the Company received net proceeds of $ 3,145 (see Note 12). The Company expects its current cash reserves to fund the Company’s operations for at least 12 months from the date of this filing. The Company’s ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future, which will primarily be accomplished by raising additional capital to meet its operating needs and repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through equity and debt financings and it expects to continue to rely on these sources of capital in the future until it is able to generate revenues. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, such financing may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. Reverse Stock Split On May 10, 2023, the Company effected a 1-for-2.5 reverse stock split of its common stock. The par value and the authorized shares of the Company’s common stock were not adjusted as a result of the reverse stock split. The accompanying consolidated financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented. F- 6 Reincorporation The Company’s Certificate of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company’s conversion from a California corporation into a Delaware corporation, authorizes the Company to issue up to 120,000,000 shares, consisting of 100,000,000 shares of common stock, par value of $ 0.001 per share, and 20,000,000 shares of preferred stock, par value $ 0.001 per share. The accompanying consolidated financial statements and notes to the financial statements give retroactive effect to the reincorporation for all periods presented. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The accompanying consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying consolidated financial statements include the valuation allowance on deferred tax assets and impairment analysis and useful life for intangible assets. Cash Cash includes currency on hand with banks and financial institutions. The Company had no restrictions on its cash balances at December 31, 2024 and 2023. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception. Vendor Advances The Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock, depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors totalled $ 3,115 , with $ 2,615 being paid in cash and $ 500 being paid with shares of the Company’s common stock (see Note 6). Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $ 256 , with an unamortized balance of $ 2,859 as of December 31, 2024. F- 7 Intangible Assets The Company’s intangible asset consists of patents that the Company acquired through its acquisition of Enviro Therapeutics, Inc. during the year ended December 31, 2021, with an acquisition cost of $ 800 . Amortization expense relating to the intangible asset during the years ended December 31, 2024 and 2023 was $ 160 , respectively, with an unamortized balance of $ 222 and $ 382 at December 31, 2024 and 2023, respectively. Amortization expense for the years ended December 31, 2025 and 2026 will be $ 160 and $ 62 , respectively. Impairment of Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment , which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable regardless of whether such carrying amount is zero or negative. If the estimated undiscounted future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. No impairment was recorded relating to the Company’s intangible asset during the years ended December 31, 2024 and 2023. Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings Per Share . Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive securities are converted. When options or warrants are outstanding, dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and funds obtained thereby are assumed to be used to purchase common stock at the average market price during the period. For the years ended December 31, 2024 and 2023, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At December 31, 2024 and 2023, the potentially dilutive securities consisted of 278,188 and 150,000 shares of common stock issuable upon exercise of outstanding common stock purchase warrants, respectively, and 172,000 shares issuable upon vesting of unvested restricted stock units (“RSUs”) as of December 31, 2024. Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statement of operations. As of December 31, 2023, the Company had incurred $ 482 of deferred offering costs related to the Company’s IPO. During the year ended December 31, 2024, a total of $ 872 of deferred offering costs were recorded against the net proceeds received from the IPO, and $ 1,377 were incurred relating to the Company’s potential Equity Line of Credit (see Notes 6 and 7). F- 8 Fair Value Measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. The carrying amounts of the Company’s convertible notes payable approximate their fair values as the interest rates of the notes are based on prevailing market rates. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a 100 % valuation allowance against its deferred tax assets as of December 31, 2024 and 2023. The Company accounts for uncertainty in income taxes using a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are therefore expensed as incurred and are included in General and administrative expenses on the accompanying consolidated Statements of Operations. Patent expenses were $ 134 and $ 45 during the years ended December 31, 2024 and 2023. Research and Development Costs The Company expenses its research and development costs as incurred. Research and developments costs for the years ended December 31, 2024 and 2023 were $ 810 and $ 82 , respectively. Research Contract Costs and Accruals The Company has entered into various research and development-related contracts with companies inside the United States. These agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. F- 9 Stock-Based Compensation The Company measures all stock options, certain warrants and other stock-based awards granted based on the fair value of the award on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these awards using the straight-line method over the requisite service period. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company was a private company until the completion of its IPO on September 17, 2024. The Company estimates the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms’ length transactions, the rights and preferences of securities senior to the Company’s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options or warrants at each valuation date, as applicable. The fair value of each stock option or warrant grant is estimated using the Black-Scholes option-pricing model. Until the completion of its IPO, the Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options or warrants. The expected term of stock options or warrants granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero , based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Marketing and Advertising Costs Marketing and advertising expenses were not material for the years ended December 31, 2024 and 2023. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, Segment Reporting, including the significant segment expense disclosures. The Company adopted ASU 2023-07 beginning January 1, 2024. The adoption of this new guidance did not have a material impact to its financial position, results of operations and cash flows. In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures. F- 10 Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements. NOTE 3 – ADVANCES FROM RELATED PARTIES During the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $ 14 . The advances accrued no interest, were unsecured and were due on demand. During the year ended December 31, 2022, the Company repaid $ 10 of the advances, and as of December 31, 2023 and September 17, 2024 (the date of the closing of the Company’s IPO), a total of $ 4 was outstanding. During the three months ended September 30, 2024, the officers agreed to automatically convert the principal into shares of the Company’s common stock upon the closing of the IPO transaction. Upon the closing of the IPO, all of the principal automatically converted into 1,664 shares of the Company’s common stock based on the conversion price of $ 2.40 , which was 60% of the IPO closing price of $ 4.00 . As the officers received 666 additional shares based on the 40 % discounted price, the fair value of those shares, $ 3 , was recorded as a financing cost during the year ended December 31, 2024. As of December 31, 2024, no principal or interest was due on the advances. During the year ended December 31, 2024, the Company entered into agreements with CEO.CA Technologies Ltd. and Belair Capital Advisors Inc., shareholders of the Company, pursuant to which they will provide certain services to the Company. The Company made payments of $ 250 and $ 365 , respectively, to these companies as advances for future services to be performed (see Note 7). NOTE 4 – NOTES PAYABLE - OFFICERS During the year ended December 31, 2024, the Company entered into note payable agreements with three of its officers in the aggregate total of $ 142 . The notes accrued interest at 7.5 % per annum, were unsecured and were due one year from the date of issuance. During the year ended December 31, 2024, the principal of $ 142 and accrued interest of $ 3 were repaid. In connection with the loans, the Company issued the officers 36,270 shares of the Company’s common stock. The Company valued the shares on the date of grant to be $ 89 (see Note 6). The value of the shares was recorded in general and administrative expenses during the year ended December 31, 2024. No amounts were owed to the officers as of December 31, 2024. NOTE 5 – CONVERTIBLE NOTES PAYABLE During the year ended December 31, 2022, the Company entered into several convertible note payable agreements with certain investors totaling $ 675 . The notes accrued interest at 6 % per annum, were unsecured, due by April 2025, and automatically converted into shares of the Company’s common stock upon completion of an IPO. In the event the Company did not close an IPO transaction within 12 months of the date of the note, the Company had the choice of paying off the principal plus all accrued and unpaid interest, or the note’s principal balance will increase to 110% of its original balance. The notes were convertible at the option of the noteholders into shares of the Company’s common stock at a price per share as defined in the agreement or automatically convertible into shares of the Company’s common stock at 60% of the IPO price per share upon the closing of an IPO transaction. The net proceeds to the Company relating to the convertible notes, was $ 564 . As of December 31, 2022, $ 675 of principal was outstanding on the notes, in addition to $ 17 of accrued and unpaid interest. During the year ended December 31, 2023, no principal or interest payments were made on the notes and the notes accrued interest of $ 43 . As the Company did not close its IPO transaction within 12 months of the date of the notes, the notes’ principal balance increased to 110% of their original balance, or an increase of $ 68 . As of December 31, 2023, $ 743 of principal was outstanding on the notes and $ 60 of accrued and unpaid interest. F- 11 The Company accounted for the $ 68 increase in the principal balance as a debt discount. During the year ended December 31, 2023, the Company amortized $ 16 of debt discount, leaving an unamortized balance of $ 52 as of December 31, 2023. Also, in connection with the convertible note agreements, the Company incurred debt issuance costs of $ 111 , which the Company recorded as a debt discount during the year ended December 31, 2022. During the year ended December 31, 2022, the Company amortized $ 18 of debt discount, leaving an unamortized balance of $ 93 at December 31, 2022. During the year ended December 31, 2023, the Company amortized $ 40 of debt discount, leaving an unamortized balance of $ 53 as of December 31, 2023. As of December 31, 2023, there was a total unamortized balance of $ 105 . During the year ended December 31, 2024, as the Company did not close its IPO transaction within 12 months of the date of the notes, a portion of the notes’ principal balance increased to 110% of their previous balance, or an increase of $ 49 . The Company accounted for the $ 49 increase in the principal balance as a debt discount, leaving an unamortized balance of $ 154 as of September 17, 2024. As of September 17, 2024, $ 792 of principal was outstanding on the notes and $ 92 of accrued and unpaid interest. Upon closing of the Company’s IPO on September 17, 2024, the principal amount of $ 792 , plus the accrued and unpaid interest of $ 92 , totaling $ 884 , automatically converted into 368,371 shares of the Company’s common stock based on the principal and accrued interest due as of September 17, 2024. Also, the unamortized balance of the debt discount of $ 154 was amortized during the period, leaving no unamortized balance as of December 31, 2024. No principal or interest was owed on the notes as of December 31, 2024. NOTE 6 – SHAREHOLDERS’ EQUITY Common Stock Authorized Shares The Company’s Certificate of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company’s conversion from a California corporation into a Delaware corporation, authorizes the Company to issue up to 120,000,000 shares, consisting of 100,000,000 shares of common stock, par value of $ 0.001 per share, and 20,000,000 shares of preferred stock, par value $ 0.001 per share. Holders of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared from time to time by the board of directors out of funds legally available and share pro rata in any distributions with shareholders upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of December 31, 2024 and 2023, there were 13,736,597 and 10,562,640 shares of common stock issued and outstanding, respectively, and no shares of preferred stock outstanding. Common Shares Issued in Connection with a Shareholder Dispute During the year ended December 31, 2023, the Company issued 228,284 shares of its common stock to two shareholders relating to the settlement of a dispute. The Company valued the shares on the date of grant to be $ 912 . The value of the shares was recorded in general and administrative expenses during the year ended December 31, 2023. Upon the issuance of the shares, the shareholders entered into agreements with the Company under which they agreed to the final settlement of the dispute. Common Stock Issued for Cash Upon Closing of the Company’s IPO On September 17, 2024, the Company completed the IPO of its common stock in which the Company issued and sold 1,550,000 shares of its common stock at a public offering price of $ 4.00 per share. The total gross proceeds of the IPO were $ 6,200 and the Company raised $ 5,524 in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company, excluding deferred offering costs of $ 872 . The underwriters were granted a 45-day option to purchase up to an additional 232,500 shares of common stock from the Company. No additional shares were sold under the 45-day option. F- 12 On September 17, 2024, pursuant to the underwriting agreement, the Company issued common stock purchase warrants to the underwriters to purchase up to 108,500 shares of the Company’s common stock, at an exercise price of $ 4.80 per share, subject to adjustments. The warrants will be exercisable during the period commencing on March 16, 2025 and ending on September 17, 2029, and may be exercised on a cashless basis under certain circumstances. Common Stock Issued Upon Conversion of Accounts Payable During the year ended December 31, 2024, the Company entered into an agreement with Cedars-Sinai Medical Center (“Cedars”) under which Cedars agreed to convert $ 750 of the total accounts payable due to them into 312,500 shares of the Company’s common stock, with such conversion to occur upon the closing of the Company’s IPO. The conversion price of the shares was equal to 60 % of the per share IPO price, or $ 2.40 per share. Upon the closing of the IPO, the shares were issued to Cedars and the debt was forgiven. The fair value of the shares was $ 1,250 . The Company recorded the difference between the fair value of the shares and the debt forgiven as a financing cost of $ 500 , which was recorded during the year ended December 31, 2024. Also, during the year ended December 31, 2024, the Company entered into another agreement with Cedars under which Cedars agreed to convert $ 200 of the total accounts payable due to them into 150,830 shares of the Company’s common stock. The conversion price of the shares was equal to 60 % of the closing price of the Company’s common stock on the date of the agreement, or $ 1.33 per share. The fair value of the shares was $ 333 . The Company recorded the difference between the fair value of the shares and the debt forgiven as a financing cost of $ 133 , which was recorded during the year ended December 31, 2024. During the year ended December 31, 2024, the Company entered into an agreement with its Chief Financial Officer (“CFO”), under which he agreed to convert $ 172 of the total accounts payable due to him into 51,610 shares of the Company’s common stock with such conversion to occur upon the closing of the Company’s IPO. The conversion price of the shares was equal to 83 % of the IPO price. Upon the closing of the IPO, the shares were issued to the CFO. The fair value of the shares was $ 206 . The Company recorded the difference between the fair value of the shares and the accounts payable forgiven as a financing cost of $ 34 , which was recorded during the year ended December 31, 2024. No amounts were owed to the CFO as of December 31, 2024. In summary, during the year ended December 31, 2024, the company issued 514,940 shares of its common stock with a fair value of $ 1,789 relating to the conversion of its account payable. Common Stock Issued for Advances to Vendors On October 1, 2024, the Company entered into a consulting agreement with Cross Current Capital LLC (“Cross Current”) and Alan Masley (the “Advisor”) pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company (see Note 7). For the services to be rendered under the agreement, the Company agreed to issue to the Advisor restricted shares of the Company’s common stock (RSUs) in an amount equal to $ 500 , which RSUs are subject to a six-month vesting period and will be subject to a “true up” at the end of the vesting period on April 1, 2025. On the date of the agreement, the Company issued 367,647 RSUs to the Advisor based on the closing price of the Company’s common stock on that date. The Company accounted for the value of the RSU as an advance to the vendor for future services to be performed (see Note 2). None of these RSUs vested and no shares were issued during the year ended December 31, 2024. If at April 1, 2025, the shares issued to the Advisor are valued at less than $ 500 based on the closing price of the Company’s common stock on that day, additional shares will be issued to the Advisor as a “true up.” In the event the shares are valued at more than $ 500 on April 1, 2025, the Advisor will be required to return any shares to the Company in excess of the $ 500 value. Common Stock Issued for Deferred Offering Costs On November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (“Helena”) pursuant to which Helena agreed to provide certain financial services to the Company (see Note 7). In exchange for the services, the Company issued Helena 670,641 shares of its common stock, which shares were equal to $ 900 divided by the lowest one-day VWAP during the five trading days immediately preceding entry into the agreement and valued at $ 1,378 on the date of issuance. The Company accounted for the value of the shares issued as an advance to the vendor for future services to be performed (see Note 2). The shares issued to Helena will be subject to a “true up” after the registration statement is declared effective, at which time additional shares will be issuable to Helena in the event the value of the shares is less than $ 900 (or shares will be returned by Helena to the Company in the event the shares are valued at more than $ 900 ). F- 13 Grant of Restricted Stock Units (RSUs) The following table summarizes restricted stock unit activity during the year ended December 31, 2024: SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY Number of Restricted Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2023 — $ — $ — Granted 240,341 532 2.21 Vested ( 68,341 ) ( 218 ) 3.19 Forfeited — — — Non-vested, December 31, 2024 172,000 $ 314 $ 1.83 Common Stock Issued for Services On September 23, 2024, the Company entered into a strategic advisory agreement with Belair Capital Advisors Inc. (“Belair”). During the one-year term of the agreement, in exchange for its services, the Company issued Belair 50,000 RSUs, which vest six months from the date of issuance. The fair value of the shares on the date of grant was $ 100 , which value will be amortized over the one-year service period of the agreement. None of these shares vested or were issued during the year ended December 31, 2024. During the year ended December 31, 2024, the Company recorded $ 29 of stock compensation for the fair value vesting of this restricted common stock. Officer Compensation Upon the closing of the Company’s IPO, the Company entered into agreements with each of its four officers. Such agreements provided for annual cash compensation and annual grants of RSUs in accordance with the terms of the Company’s 2023 Equity Incentive Plan. The RSU grants vest annually and are subject to full acceleration of vesting upon the sale of the Company. Upon the closing of the IPO, the Company granted the officers 92,000 RSUs. The fair value of the shares on the date of grant was $ 226 . None of these RSUs vested or were converted into shares of common stock during the year ended December 31, 2024. During the three months ended December 31, 2024, the Company issued its CFO 32,071 RSUs relating to bonus RSUs issued as a result of the completion of the Company’s IPO. The Company valued the RSUs on the date of the grant to be $ 42 . The RSUs vested upon the date of grant and were issued to the CFO. During the year ended December 31, 2024, the Company recorded $ 93 of stock compensation for the fair value vesting of this restricted common stock. Loans from Officers During the year ended December 31, 2024, the Company entered into note payable agreements with three of its officers in the aggregate amount of $ 142 (see Note 4). In consideration for making the loans to the Company, the Company issued the officers 36,270 shares of the Company’s common stock. The Company valued the shares on the date of grant to be $ 89 . The shares vested upon grant and were issued to the officers. During the year ended December 31, 2024, the Company recorded $ 89 of stock compensation for the fair value vesting of this restricted common stock. F- 14 Director Compensation Upon the closing of the Company’s IPO, the Company entered into director agreements with each of its three independent directors. Such agreements provide for annual cash compensation of $ 50 , payable in quarterly installments in arrears, plus an additional $ 10 cash compensation for the chair of the audit committee. In addition, the Company’s policy provides that, upon initial election or appointment to our board of directors, each new non-employee director will be granted a one-time grant, or Director Initial Grant, of 10,000 RSUs that will vest in substantially equal annual installments over a period of three years. The Director Initial Grant is subject to full acceleration of vesting upon the sale of the Company, in accordance with the terms of the Company’s 2023 Equity Incentive Plan. The 30,000 RSUs were granted effective on the IPO closing date. The fair value of the shares on the date of grant was $ 74 . None of these shares vested or were issued during the year ended December 31, 2024. During the year ended December 31, 2024, the Company recorded $ 7 of stock compensation for the fair value vesting of restricted common stock. RSU Summary During the year ended December 31, 2024, the Company recorded $ 218 of stock compensation-related expense for the fair value vesting of restricted common stock. As of December 31, 2024, $ 314 of unamortized compensation remained. Adoption of the 2023 Equity Incentive Plan In July 2023, the Company’s board of directors and stockholders adopted the 2023 Equity Incentive Plan (the “2023 Plan”). Under the 2023 Plan, the Company may grant incentive stock options to employees, including employees of any parent or subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and other forms of stock compensation to employees, directors and consultants, including employees and consultants of the Company’s affiliates. As approved, a total of 1,650,000 shares of common stock were initially reserved for issuance under the 2023 Plan. No shares were issued under the 2023 Plan as of December 31, 2023 and there were a total of 172,000 RSUs outstanding under the 2023 Plan as of December 31, 2024. As of December 31, 2024, a total of 1,478,000 shares remained available for issuance under the 2023 Plan. F- 15 Stock Warrants The table below summarizes the Company’s warrant activities for years ended December 31, 2023 and 2024: SCHEDULE OF WARRANT ACTIVITY Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, December 31, 2022 180,000 $ 4.17 - 8.33 $ 4.86 Granted – – – Cancelled – – – Exercised – – – Forfeited/Expired ( 30,000 ) 8.33 8.33 Balance, December 31, 2023 150,000 4.17 4.17 Granted 128,188 2.40 - 4.80 4.43 Cancelled – – – Exercised – – – Forfeited/Expired – – – Balance, December 31, 2024 278,188 $ 2.40 - 4.80 $ 4.29 Vested and exercisable, December 31, 2024 169,688 $ 2.40 - 4.17 $ 3.96 The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.40 19,688 4.75 $ 2.40 19,688 4.75 $ 2.40 4.17 - 4.80 258,500 2.14 4.43 150,000 0.25 4.17 $ 2.40 - 4.17 278,188 2.32 $ 4.29 169,688 0.77 $ 4.17 During the year ended December 31, 2022, the Company entered into a convertible note payable agreement with an individual in the amount of $ 250 . In connection with that agreement, the Company granted a warrant to the lender to purchase up to 150,000 shares of the Company’s common stock with an exercise price of $ 4.17 per share. The warrant vested upon grant and expires in March 2025. On September 17, 2024, upon the closing of the IPO, the Company issued stock warrants to the participating underwriters for the purchase of up to 108,500 shares of the Company’s common stock, at an exercise price of $ 4.80 per share, subject to adjustment. The warrants will be exercisable during the period commencing on March 16, 2025, and ending on September 16, 2029, and may be exercised on a cashless basis under certain circumstances. On September 17, 2024, upon the closing of the IPO, the Company issued a stock warrant to the underwriters for the purchase of 19,688 shares of common stock at an exercise price of $ 2.40 per share. The warrant vested upon grant. The warrant was issued to the underwriters as they were the placement agents for the convertible notes payable (see Note 5). The Company valued the warrant using a Black-Scholes pricing model with the following weighted average assumptions: fair value of the Company’s stock price of $ 2.46 per share, the expected term of 2.5 years, volatility of 100 %, dividend rate of 0 %, and risk-free interest rate of 3.49 %. The fair value of the warrant of $ 29 was recorded to general and administrative expense during the year ended December 31, 2024. The warrant expires five years from the date of grant. There was no intrinsic value for warrant shares outstanding at December 31, 2024. F- 16 NOTE 7 – COMMITMENTS Kairos Agreement with Prevail Infoworks, Inc. In August 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (“Prevail”), pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company must make an advance payment of $ 900 to Prevail before they begin their services and, at such time as we notify Prevail to engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $ 80 per month during the time Prevail performs clinical research services for the Company’s Phase 2 ENV 105 prostate and Phase 1 ENV 105 lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days’ written notice to the other party. The Company made the advance payment to Prevail in October 2024 (see Note 8). As part of the agreement, the Company must make an advance payment of $ 900 to Prevail before they begin their services. The Company made the advance payment to Prevail in October 2024. The payment of $ 900 is included in vendor advances on the accompanying balance sheet as of December 31, 2024 (see Note 2). Kairos Agreement with PreCheck Health Services, Inc. On September 20, 2024, the Company entered into a bioassay services agreement (the “Bioassay Services Agreement”) with PreCheck Health Services, Inc., a Florida-based corporation (“PreCheck”). Pursuant to the Bioassay Services Agreement, PreCheck will provide certain biomarker screening services for the Company’s ongoing carotuximab (ENV105) clinical trials in order to assist the Company in identifying lung and prostate cancer patients suitable to the Company’s ongoing Phase 1 clinical trials for lung cancer patients and Phase 2 trials for patients with castrate resistant prostate cancer. In order to identify biomarkers for patient screening and therapy monitoring using carotuximab (ENV105), PreCheck will utilize its SolidTumorCheck+ platform for the somatic gene expression analysis of biopsy tissue samples derived from patients with lung and prostate cancer, as part of the Company’s ongoing clinical trials. In furtherance of these efforts, PreCheck will develop a companion diagnostic to support its identification of such patients with a three gene PCR analysis or other genetic analysis, which diagnostic test will then be developed and submitted to the Food and Drug Administration (“FDA”) for castrate-resistant prostate cancer patients and for lung cancer patients on Tagrisso. In exchange for PreCheck’s services, and according to the terms of the Bioassay Services Agreement, the Company paid $ 900 to PreCheck as an advance for the future laboratory services to be performed. The payment of $ 900 is included in vendor advances on the accompanying balance sheet as of December 31, 2024 (see Note 2). The term of the agreement is one year from the effective date. Kairos Agreement with CEO.CA Technologies Ltd. On September 23, 2024, the Company entered into an advisory and consulting services agreement (the “CEO.CA Agreement”) with CEO.CA Technologies Ltd., a Canadian company (“CEO.CA”), pursuant to which CEO.CA will provide certain internet-based financial information and communications services for a period of one year for a services fee of $ 250 . The service fee is an advance on future services to be performed. The CEO.CA Agreement includes such services as strategic news placement, news releases, interviews, monthly analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification clauses and governing law clauses. The payment of $ 250 is included in vendor advances on the accompanying balance sheet as of December 31, 2024 (see Note 2). F- 17 Kairos Agreement with Belair Capital Advisors Inc. On September 23, 2024, the Company entered into a strategic advisory agreement (the “Strategic Advisory Agreement”) with Belair Capital Advisors Inc. (“BCA”). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic Advisory Agreement, in exchange for its services, the Company will pay BCA a $ 365 fee and will issue BCA 50,000 RSUs, which will vest at the end of six months following the date of issuance. The payment of $ 365 is included in vendor advances on the accompanying balance sheet as of December 31, 2024 (see Note 2). Kairos Agreement with Cross Current Capital LLC On October 1, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Cross Current Capital LLC, a limited liability company organized under the laws of Puerto Rico (“Cross Current”), and Alan Masley (the “Advisor”), pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help in drafting marketing materials and presentations, (d) reviewing the Company’s business requirements and discuss financing and businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor introductions, (i) investment banking and research introductions, (j) M&A canvassing and ways to grow the business organically, and (k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $ 200,000 in cash and agreed to issue to the Advisor restricted shares of the Company’s common stock, issuable under the Company’s 2023 Plan, in an amount equal to $ 500,000 (the “Shares”), which Shares shall vest at the end of six months after issuance. On the date of the agreement, the Company agreed to issue 367,647 shares of its common stock to the Advisor based on the closing price of the Company’s common stock on that date. The term of the Consulting Agreement is 24 months and can be extended for another 12 months upon the written consent of both parties. The Company made the $ 200 payment in October 2024. The payment of $ 200 and the value of the shares issued of $ 500 are included in vendor advances on the accompanying balance sheet as of December 31, 2024. The 367,647 shares will be subject to a “true up” on April 1, 2024, at which time additional shares will be issued to the Advisor (or returned by the Advisor to the Company) in order to ensure the shares are valued at $ 500 as of April 1, 2024. Agreement with Helena Global Investment Opportunities On November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (“Helena”) pursuant to which the Company will have the right to issue and sell to the Helena, from time to time, and Helena shall purchase from the Company, up to $ 30,000 of the Company’s shares of common stock (the “Equity Line of Credit”). The Equity Line of Credit will become available to the Company at such time as it files a registration statement on Form S-1 registering the shares issuable under the Equity Line of Credit. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares of common stock, calculated using $ 900 divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement. The Company has agreed to register such shares for resale pursuant to a registration statement on Form S-1. In exchange for the services, the Company issued Helena 670,641 shares of its common stock valued at $ 1,378 on the date of issuance. The Company accounted for the value of the shares issued as deferred offering costs (see Note 2). The shares vested on the date of the agreement, were issued to Helena, and are subject to a “true up” based upon the value of the stock at the time the company files and obtains effectiveness of a registration statement registering the shares for resale. Kairos Exclusive License Agreements with Cedars-Sinai Medical Center (Cedars) The Company has entered into four Exclusive License Agreements with Cedars, each of which grants the Company licensing rights with respect to certain patent rights owned by Cedars as follows: 1. Methods of use of compounds that bind to RelA of NFkB; 2. Composition and methods for treating fibrosis; 3. Compositions and methods for treating cancer and autoimmune diseases; and 4. Method of generating activated T cells for cancer therapy. F- 18 For each of the exclusive license agreement in items 1, 2 and 3, the Company was required to pay an initial license fee of $ 5 , reimburse Cedars for patent protection costs ranging from approximately $ 9 to $ 61 , pay an annual maintenance fee of $ 10 , and pay royalties based on 3.75 % of net sales and pay other non-royalty sublicense fees ranging from 5 % to 35 % of sales of products. In addition, for items 1, 2 and 3, the Company is required to pay Cedars based on the following milestones: ● $ 150 upon the successful completing of Phase I clinical trial; ● $ 250 (for items 1 and 2) and $ 500 (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt of Food and Drug Administration (“FDA”) approval for a Phase III clinical trial; ● $ 1,500 upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial market; and ● $ 250 upon cumulative net sales exceeding $ 5,000 . For the exclusive license agreement in item 4, the Company is required to pay an initial license fee of $ 50 upon the raising of $ 500 in capital, pay an annual maintenance fee of $ 10 , pay royalties based on 4.25 % of patent product sales and 0.5 % of other sales and pay other non-royalty sublicense fees ranging from 5 % to 35 %. In addition, the Company is required to pay Cedars based on the following milestones: ● $ 150 upon the successful completing of Phase I clinical trial; ● $ 250 upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (“FDA”) or equivalent regulatory agency in another jurisdiction approval for a Phase III clinical trial; ● $ 1,500 upon receipt of FDA approval of a new drug application; and ● $ 2,500 upon cumulative net sales exceeding $ 50,000 . Enviro Therapeutics On June 2, 2021, the Company’s wholly owned subsidiary, Enviro Therapeutics, Inc. (Enviro), entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive licensing rights (which include the right to sublicense) with respect to certain patent rights owned by Cedars, as follows: ● an Exclusive License Agreement (the “Enviro-Cedars License Agreement (Mitochondrial DNA)”) for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide related to the “Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA” invented by Dr. Neil Bhowmick and others; and ● an Exclusive License Agreement, (the “Enviro-Cedars License Agreement (Endoglin Antagonism)” and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the “Enviro-Cedars License Agreements”) for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights and technical information worldwide related to the “Sensitization of Tumors to Therapies Through Endoglin Antagonism” invented by Dr. Neil Bhowmick and others. In exchange for each of the licenses, Enviro is required to pay an upfront license fee in the mid four-figures and low-five figures, respectively. Enviro is also required to reimburse Cedars for the costs in the mid-to-high six figures incurred in the prosecution of the patent rights subject to the Enviro-Cedars License Agreements prior to the date of execution of such agreements, and certain costs and fees then outstanding aggregating in the low-six figures owed by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License Agreements, Cedars shall also receive royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and less than one percent of net sales of other products derived from Cedars’ technical information, with a minimum annual royalty fee in the low five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars License Agreements. To the extent Enviro derives non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues would be due and payable to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization at the time the sublicense revenue is generated. F- 19 Enviro is also required to pay Cedars in connection with achieving the following Payment Milestones relating to products derived from the patent rights: successful completion of a Phase I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval, and approval for a Phase III clinical trial; FDA approval of an NDA or BLA; cumulative net sales exceeding $ 50,000 ; and cumulative net sales exceeding $ 100,000 . If all of these payment milestones are met among both of the Enviro-Cedars License Agreements, the required milestone payments would total in the mid-to-high seven-figures. Pursuant to the Enviro-Cedars License Agreements, Enviro is obligated to meet the following Commercialization Milestones. Pursuant to the Enviro-Cedars License Agreement (Endoglin Antagonism), Enviro is obligated to (1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro is obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses. The Enviro-Cedars License Agreements will, unless sooner terminated, continue in effect on a country-by-country basis until the last of the patents covering the patent rights or future patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived by Cedars, the agreements would automatically terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental body; (c) within 30 days for non-payment of royalties or if Enviro fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (d) within 60 days of Cedars’ failure to cure any breach or default of a material obligation under the agreements; (e) within 90 days of Enviro’s failure to cure any breach or default of a material obligation under the agreements; or (f) upon mutual written agreement of the parties. Agreement with former Chief Financial Officer The Company has an agreement with its former Chief Financial Officer that requires the Company to pay $ 50 upon the completion of raising more than $ 850 in debt or equity financing. No amount was owed at December 31, 2022 and 2023. During the year ended December 31, 2024, the Company made a payment of $ 50 to the former CFO. No amounts were owed under the agreement as of December 31, 2024. F- 20 NOTE 8 – INCOME TAXES Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2024 and 2023 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near-term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. Because of the impacts of the valuation allowance, there was no income tax expense or benefit for the years ended December 31, 2024 and 2023. A reconciliation of the differences between the effective and statutory income tax rates for the years ended December 31, 2024 and 2023 are shown below: SCHEDULE OF RECONCILIATION OF THE DIFFERENCES BETWEEN THE EFFECTIVE AND STATUTORY INCOME TAX RATES Amount Percent Amount Percent 2024 2023 Amount Percent Amount Percent Federal statutory rates $ ( 547 ) 21.0 % $ ( 381 ) 21.0 % State income taxes ( 182 ) 7.0 % ( 145 ) 7.0 % Permanent differences 102 - 3.9 % - 0.0 % Other ( 115 ) 4.4 % - 0.0 % Valuation allowance against net deferred tax assets 742 - 28.5 % 526 - 28.0 % Effective rate $ - 0.0 % $ - 0.0 % At December 31, 2024 and 2023, the significant components of the deferred tax assets are summarized below: SCHEDULE OF SIGNIFICANT COMPONENTS OF THE DEFERRED TAX ASSETS AND LIABILITIES 2024 2023 Deferred income tax assets: Net operating loss carryforwards $ 1,199 $ 857 Accrual to cash - 687 Capitalized research and development expenses 90 - Amortization of intangibles - 37 Total deferred income tax assets 1,289 1,581 Valuation allowance ( 841 ) ( 1,581 ) Total net deferred income tax assets 448 0 Deferred income tax liabilities: Amortization of intangibles ( 62 ) - Accrual to cash ( 386 ) - Total deferred income tax liabilities ( 448 ) - Total deferred income tax assets $ - $ - The Company has recorded as of December 31, 2024 and 2023 a valuation allowance of $ 841 and $ 1,581 , respectively, as it believes that it is more likely than not that the deferred tax assets will not be realized in future years. Management has based its assessment on the Company’s lack of profitable operating history. The valuation allowance increased by $ 727 and $ 477 in 2024 and 2023, respectively, primarily as a result of the Company generating additional net operating losses. The Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of December 31, 2024 and 2023. F- 21 The Company has net operating loss (“NOL”) carryforwards of approximately $ 4,300 and are subject to IRS code section 382 limitations. Of the total federal net operating loss, approximately $4,000 has an indefinite carryforward period as of December 31, 2024. The remaining federal and California net operating loss carryforwards will expire through December 31, 2044, unless previously utilized. NOL carryforwards may be subject to limitation under Sections 382 of the Internal Revenue Code, and similar state provisions which limit the amount carryforwards that can be utilized to offset future taxable income. In general, an ownership change, as defined by Sections 382, results from transactions increasing ownership of certain stockholders in the stock of the corporation by more than 50 percentage points over a three-year period. The Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss carryforwards until the time that it anticipates it will be able to utilize these tax attributes. This could impose an annual limit or reduction on the Company’s ability to utilize net operating loss carryforwards and could cause U.S. federal income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect. The U.S. federal net operating loss carryforwards are stated before any such anticipated limitations. If a change in ownership were to have occurred, the Company’s NOL carryforwards could be eliminated or restricted. NOTE 9 – GAIN ON SETTLEMENT OF ACCOUNTS PAYABLE On October 17, 2024, the Company entered into a Settlement Agreement with the Company’s former outside legal counsel. In connection with the agreement, the law firm agreed to settle the amount the Company owed them, which totaled $ 749 , in exchange for a payment of $ 150 . This resulted in a gain of $ 599 for the Company. In October 2024, the Company made the $ 150 payment to the law firm. As of December 31, 2024, no amounts were owed to the law firm. NOTE 10 – SEGMENT INFORMATION The Company operates and manages its business as one reportable segment and operates as a clinical stage biopharmaceutical company. The Company’s current focus is on developing immunotherapy and cell therapies for the treatment of cancer. The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer, who reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance. Significant segment expenses include research and development, officer compensation, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: SCHEDULE OF SEGMENT EXPENSES 2024 2023 Year ended December 31, 2024 2023 Revenue $ - $ - Less: Research and development 414 82 Officer compensation 119 - Insurance 151 29 Stock-based compensation 218 913 Operating expenses 1,441 690 Other income (expenses) ( 260 ) ( 98 ) NET LOSS $ ( 2,603 ) $ ( 1,812 ) NOTE 11 - LEGAL MATTERS To the Company’s knowledge, it is not currently the subject of any material legal proceeding. In the future, the Company may be involved in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business. NOTE 12 – SUBSEQUENT EVENTS On January 14, 2025, the Company entered into a securities purchase agreement and registration rights agreement with a select investor for the sale and issuance of 2,500,000 units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of a pre-funded warrant to purchase one share of common stock, exercisable for $ 0.001 per share, and a common warrant to purchase one and one half shares of common stock, exercisable at $ 1.399 per share. On January 16, 2025, the Company closed on the sale of the Pre-Funded Units for a total purchase price of $ 3,500 (or $ 1.40 per Pre-Funded Unit). Net proceeds received by the Company relating to the financing were $ 3,145 . On April 1, 2025, the Company issued Cross Current 166,541 shares of its common stock in connection with its agreement with Cross Current. F- 22 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None.